Published in Curr Med Res Opin on July 01, 2010
Management of hyperglycemia in geriatric patients with diabetes mellitus: South Asian consensus guidelines. Indian J Endocrinol Metab (2011) 1.43
Minimizing the risk of hypoglycemia with vildagliptin: Clinical experience, mechanistic basis, and importance in type 2 diabetes management. Diabetes Ther (2011) 1.13
Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus. Vasc Health Risk Manag (2012) 1.07
Optimal therapy of type 2 diabetes: a controversial challenge. Aging (Albany NY) (2014) 0.85
Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus. Clin Interv Aging (2013) 0.83
Efficacy and safety of vildagliptin in clinical practice-results of the PROVIL-study. World J Diabetes (2012) 0.83
Experience with vildagliptin in patients ≥75 years with type 2 diabetes and moderate or severe renal impairment. Diabetes Ther (2013) 0.79
Use of Vildagliptin in Management of Type 2 Diabetes: Effectiveness, Treatment Persistence and Safety from the 2-Year Real-Life VILDA Study. Diabetes Ther (2014) 0.79
Diabetes mellitus in elderly. Indian J Endocrinol Metab (2015) 0.77
Use of metformin and vildagliptin for treatment of type 2 diabetes in the elderly. Drug Des Devel Ther (2014) 0.77
Vildagliptin efficacy in combination with metformin among Jordanian patients with type 2 diabetes mellitus inadequately controlled with metformin. J Drug Assess (2016) 0.75
Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database. Vasc Health Risk Manag (2015) 0.75
Microtubule-dependent retrograde transport of proteins into the ER in the presence of brefeldin A suggests an ER recycling pathway. Cell (1990) 9.19
Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia (2012) 2.53
Obesity-associated gut microbiota is enriched in Lactobacillus reuteri and depleted in Bifidobacterium animalis and Methanobrevibacter smithii. Int J Obes (Lond) (2011) 2.39
The targeting of Lamp1 to lysosomes is dependent on the spacing of its cytoplasmic tail tyrosine sorting motif relative to the membrane. J Cell Biol (1996) 2.32
The endoplasmic reticulum-Golgi intermediate compartment. Curr Opin Cell Biol (1992) 2.18
Sequence and transcriptional start site of the Pseudomonas aeruginosa outer membrane porin protein F gene. J Bacteriol (1988) 2.13
Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab (2009) 2.04
Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia (2007) 2.01
Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia (2006) 1.89
Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab (2011) 1.87
Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab (2010) 1.76
The recycling pathway of protein ERGIC-53 and dynamics of the ER-Golgi intermediate compartment. J Cell Sci (1998) 1.65
Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab (2007) 1.61
An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials. Diabetes Obes Metab (2010) 1.59
Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab (2007) 1.58
Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res (2007) 1.55
Corrective osteotomy of distal radial deformities: a new method of guided locking fixed screw positioning. J Hand Surg Eur Vol (2011) 1.44
Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes Obes Metab (2010) 1.43
Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes. Diabet Med (2007) 1.43
Influence of duration of lateral decubitus on the spread of hyperbaric tetracaine during spinal anesthesia: a prospective time-response study. Anesth Analg (1994) 1.42
Circulatory failure after anesthesia induction in a patient with severe primary pulmonary hypertension. Anesthesiology (1999) 1.40
Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab (2008) 1.33
Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab (2011) 1.32
Foveal avascular zone in diabetic retinopathy: quantitative vs qualitative assessment. Eye (Lond) (2005) 1.29
A determinant in the cytoplasmic tail of the cation-dependent mannose 6-phosphate receptor prevents trafficking to lysosomes. J Cell Biol (1995) 1.28
Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes Obes Metab (2007) 1.22
Single lung transplantation for adult respiratory distress syndrome after paraquat poisoning. Thorax (1998) 1.20
Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Horm Metab Res (2008) 1.19
Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. Horm Metab Res (2008) 1.19
Interference of dapsone in HbA1c monitoring of a diabetic patient with polychondritis. Diabetes Metab (2002) 1.17
Molecular consequences of truncations of the first exon for in vitro splicing of yeast actin pre-mRNA. Nucleic Acids Res (1988) 1.16
Pseudomonas aeruginosa outer membrane lipoprotein I gene: molecular cloning, sequence, and expression in Escherichia coli. J Bacteriol (1989) 1.16
Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Obes Metab (2009) 1.14
Seasonal succession of ciliates in lake constance. Microb Ecol (1991) 1.14
Pharmacokinetics and metabolism of the anti-inflammatory agent Voltaren. Scand J Rheumatol Suppl (1978) 1.12
Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia*. Diabetes Obes Metab (2007) 1.11
Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials. Diabetes Obes Metab (2011) 1.11
A sulphonamido-indanone derivative CGP 28237 (ZK 34228), a novel non-steroidal anti-inflammatory agent without gastro-intestinal ulcerogenicity in rats. Drugs Exp Clin Res (1987) 1.11
Perioperative mortality and major cardio-pulmonary complications after lung surgery for non-small cell carcinoma. Eur J Cardiothorac Surg (1999) 1.06
Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial. Diabetologia (2011) 1.04
Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes. Diabetes Obes Metab (2014) 0.97
Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes. Horm Metab Res (2007) 0.95
C-peptide replacement improves weight gain and renal function in diabetic rats. Diabetes Metab (2006) 0.95
C-peptide, Na+,K(+)-ATPase, and diabetes. Exp Diabesity Res (2004) 0.94
Alternatives routes of insulin delivery. Diabetes Metab (2006) 0.91
A new family of orphan G protein-coupled receptors predominantly expressed in the brain. FEBS Lett (1998) 0.91
XCE, a new member of the endothelin-converting enzyme and neutral endopeptidase family, is preferentially expressed in the CNS. Brain Res Mol Brain Res (1999) 0.91
The effects ex vivo and in vitro of insulin and C-peptide on Na/K adenosine triphosphatase activity in red blood cell membranes of type 1 diabetic patients. Metabolism (2000) 0.90
Stereological changes in the capillary network and nerve cells of the aging human brain. Mech Ageing Dev (1981) 0.90
Advances in pump technology: insulin patch pumps, combined pumps and glucose sensors, and implanted pumps. Diabetes Metab (2011) 0.90
Fish oil supplementation prevents diabetes-induced nerve conduction velocity and neuroanatomical changes in rats. J Nutr (1999) 0.90
TT virus infection in French hemodialysis patients: study of prevalence and risk factors. J Clin Microbiol (1999) 0.89
Epidemiology and costs of diabetes treated with insulin in France. Diabetes Metab (2005) 0.89
Pharmacology of diclofenac sodium. Am J Med (1986) 0.88
Alteration of Na,K-ATPase isoenzymes in diabetic cardiomyopathy: effect of dietary supplementation with fish oil (n-3 fatty acids) in rats. Diabetologia (1997) 0.88
Erythrocyte Na/K ATPase activity and diabetes: relationship with C-peptide level. Diabetologia (1998) 0.88
How do patients with type 2 diabetes perceive their disease? Insights from the French DIABASIS survey. Diabetes Metab (2009) 0.87
Further characterization of the acetyl LDL (scavenger) receptor expressed by rabbit smooth muscle cells and fibroblasts. Arterioscler Thromb (1992) 0.87
Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study. Diabetes Metab (2012) 0.86
Charcot's foot: newest findings on its pathophysiology, diagnosis and treatment. Diabetes Metab (2010) 0.86
Association of diabetic neuropathy with Na/K ATPase gene polymorphism. Diabetologia (1997) 0.86
Randomized comparison of metabolic control achieved by intraperitoneal insulin infusion with implantable pumps versus intensive subcutaneous insulin therapy in type I diabetic patients. Diabetes Care (1992) 0.85
Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women. Int J Obes Relat Metab Disord (1998) 0.85
Treatment of diabetes mellitus using an external insulin pump: the state of the art. Diabetes Metab (2008) 0.85
Octreotide (long-acting release formulation) treatment in patients with graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study. J Clin Endocrinol Metab (2004) 0.85
The influence of the crimp and slope grip position on the finger pulley system. J Biomech (2009) 0.84
Determination of portal insulin absorption from peritoneum via novel nonisotopic method. Diabetes (1990) 0.84
Confirmed clinical efficacy of Actovegin in elderly patients with organic brain syndrome. Pharmacopsychiatry (1995) 0.84
MATN3 (matrilin-3) sequence variation (pT303M) is a risk factor for osteoarthritis of the CMC1 joint of the hand, but not for knee osteoarthritis. Ann Rheum Dis (2007) 0.84
The influence of concentric and eccentric loading on the finger pulley system. J Biomech (2009) 0.84
Daytime fluctuations of plasminogen activator inhibitor 1 (PAI-1) in populations with high PAI-1 levels. Thromb Haemost (1992) 0.83
Treating type 2 diabetes: how safe are current therapeutic agents? Int J Clin Pract (2009) 0.83
Pharmacodynamics of the glucagon-like peptide-1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulphonylureas with/without metformin. Diabetes Obes Metab (2014) 0.83
Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies. Diabetes Metab (2008) 0.83
Aggressive multimodal therapy of sporadic malignant insulinoma can improve survival: a retrospective 35-year study of 12 patients. Diabetes Metab (2008) 0.82
GLP-1: what is known, new and controversial in 2010? Diabetes Metab (2010) 0.82
Surveillance of nosocomial transmission of Candida albicans in an intensive care unit by DNA fingerprinting. J Hosp Infect (2003) 0.81
Organization and chromosomal localization of the human ECEL1 (XCE) gene encoding a zinc metallopeptidase involved in the nervous control of respiration. Biochem J (2000) 0.81
Real-life comparison of DPP4-inhibitors with conventional oral antidiabetics as add-on therapy to metformin in elderly patients with type 2 diabetes: the HYPOCRAS study. Diabetes Metab (2012) 0.81
Comparison of hypobaric, hyperbaric, and isobaric solutions of bupivacaine during continuous spinal anesthesia. Anesth Analg (1991) 0.80
Alterations of Na,K-ATPase isoenzymes in the rat diabetic neuropathy: protective effect of dietary supplementation with n-3 fatty acids. J Neurochem (1998) 0.80
Evidence of time-dependent changes in renal medullary Na,K-ATPase activity and expression in diabetic rats. Cell Mol Biol (Noisy-le-grand) (2001) 0.80
C-Peptide effects on renal physiology and diabetes. Exp Diabetes Res (2008) 0.80
Percutaneous tenodesis of the Achilles tendon. A new surgical method for the treatment of acute Achilles tendon rupture through percutaneous tenodesis. Injury (1999) 0.80
Na,K-atpase alterations in diabetic rats: relationship with lipid metabolism and nerve physiological parameters. Cell Mol Biol (Noisy-le-grand) (2001) 0.79
Differential effect of omega3 PUFA supplementations on Na,K-ATPase and Mg-ATPase activities: possible role of the membrane omega6/omega3 ratio. J Membr Biol (2003) 0.79
Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. French Fluvastatin Study Group. Am J Cardiol (2000) 0.79
Localization of Na,K-ATPase alpha/beta isoforms in rat sciatic nerves: effect of diabetes and fish oil treatment. J Neurochem (1999) 0.79
Endothelin-converting enzyme-like 1 (ECEL1; 'XCE'): a putative metallopeptidase crucially involved in the nervous control of respiration. Biochem Soc Trans (2000) 0.79
Postmortem changes in stereological parameters of cerebral neurons. Pathol Res Pract (1980) 0.79
Aplasia of the flexor digitorum profundus tendon of the small finger. J Hand Surg Eur Vol (2006) 0.79
Time course of GH and IGF-1 levels following withdrawal of long-acting octreotide in acromegaly. Pituitary (2000) 0.79
Quantitative determination of drugs in biological materials by means of extractive alkylation and gas-liquid chromatography. J Chromatogr (1977) 0.78
Relationship between triglycerides and factor VIIc and plasminogen activator inhibitor type-1: lack of threshold value. Thromb Res (1999) 0.78